American Well Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$AMWL
Business Services
Consumer Discretionary
Get the next $AMWL alert in real time by email
8-K
0001393584false00013935842025-02-122025-02-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2025

 

 

American Well Corporation

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39515

20-5009396

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

75 State Street

26th Floor

 

Boston, Massachusetts

 

02109

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 617 204-3500

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Class A Common Stock, $0.01 Par Value

 

AMWL

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On February 12, 2025, American Well Corporation (the "Company") announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company's Earnings Report is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.

 

The Company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com.

 

The information contained in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being filed herewith:

99.1

Earnings Report, dated February 12, 2025, issued by American Well Corporation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AMERICAN WELL CORPORATION

 

 

 

 

Date:

February 12, 2025

By:

/s/ Bradford Gay

 

 

 

Bradford Gay
Senior Vice President, General Counsel

 


Get the next $AMWL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AMWL

DatePrice TargetRatingAnalyst
1/13/2025$15.00Equal Weight → Overweight
Wells Fargo
8/3/2023$5.00 → $2.50Overweight → Equal-Weight
Morgan Stanley
3/23/2023$5.00 → $2.50Outperform → Market Perform
TD Cowen
2/27/2023$5.00 → $3.50Overweight → Neutral
Piper Sandler
1/4/2023$4.20Neutral → Buy
BofA Securities
9/7/2022$5.00Hold
Truist
4/14/2022$6.00Buy
Guggenheim
4/1/2022$5.00Neutral
Credit Suisse
More analyst ratings

$AMWL
Press Releases

Fastest customizable press release news feed in the world

See more
  • Amwell makes inducement grant

    BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units ("RSUs") covering 220,844 shares of its Class A common stock to Dan Zamansky. The grant was offered as material inducement to Zamansky's employment as Amwell's chief product and technology officer. The RSUs become vested as follows, subject to Zamansky's continued employment through each vesting date, except as noted below: 25% of the RSUs will vest on the six-month anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro-rata increments every three (3) m

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell announces innovation leader as chief product and technology officer

    BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, announced Dan Zamansky, an industry leader in innovation and technology, as the company's new chief product and technology officer, effective today. Zamansky will lead the company's product and R&D organizations. He will focus on the comprehensive technology-enabled care platform Amwell offers payers and health systems to provide individuals with better access to more convenient, affordable and effective care. In addition, as more people seek care online and more clinical programs are available, Zamansky will ensure the Amwell platform continues to evolve and provide clients with an integr

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell® makes grants to new employees under inducement plan

    BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on Feb. 18, Amwell made grants of RSUs covering an aggregate of 16,737 shares of its Class A common stock to four new employees. The grants were offered as material inducement to the employees' employment with Amwell. The RSUs will vest as follows, subject to the applicable employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first

    $AMWL
    Business Services
    Consumer Discretionary

$AMWL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AMWL
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AMWL
SEC Filings

See more

$AMWL
Leadership Updates

Live Leadership Updates

See more
  • Amwell announces new chief financial officer

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell Announces Appointment of Ricky Goldwasser to its Board of Directors

    Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

    $AMWL
    Business Services
    Consumer Discretionary
  • Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

    ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

    $AMWL
    $AXGN
    Business Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$AMWL
Financials

Live finance-specific insights

See more
  • Amwell® Announces Results for Fourth Quarter and Full Year 2024

    BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell® to report fourth quarter and full year 2024 operating results

    BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Am

    $AMWL
    Business Services
    Consumer Discretionary
  • Amwell Announces Results for Third Quarter 2024

    BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the third quarter ended Sept. 30, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the third quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Oct. 30. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID number 7830032. A replay of the call will

    $AMWL
    Business Services
    Consumer Discretionary

$AMWL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more